GlaxoSmithKline Rating Reiterated by AlphaValue (GSK)
GlaxoSmithKline (LON:GSK)‘s stock had its “sell” rating restated by research analysts at AlphaValue in a report released on Thursday, AnalystRatings.Net reports. They currently have a GBX 1,411 ($22.64) price objective on the stock. AlphaValue’s price target indicates a potential downside of 8.97% from the company’s current price.
Shares of GlaxoSmithKline (LON:GSK) traded down 0.23% during mid-day trading on Thursday, hitting GBX 1546.50. The stock had a trading volume of 5,084,437 shares. GlaxoSmithKline has a 52 week low of GBX 1314.00 and a 52 week high of GBX 1816.00. The stock’s 50-day moving average is GBX 1652. and its 200-day moving average is GBX 1640.. The company’s market cap is £74.928 billion.
GSK has been the subject of a number of other recent research reports. Analysts at Berenberg Bank reiterated a “buy” rating on shares of GlaxoSmithKline in a research note to investors on Tuesday. They now have a GBX 1,795 ($28.80) price target on the stock. Separately, analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GlaxoSmithKline in a research note to investors on Tuesday. They now have a GBX 1,900 ($30.48) price target on the stock. Finally, analysts at Panmure Gordon reiterated a “buy” rating on shares of GlaxoSmithKline in a research note to investors on Friday, October 4th. They now have a GBX 1,850 ($29.68) price target on the stock. Five investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have assigned a buy rating to the company. The company has an average rating of “Hold” and an average target price of GBX 1,647.27 ($26.43).
GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.